Suppr超能文献

识别疑似家族性乳糜微粒血症综合征。

Identifying suspected familial chylomicronemia syndrome.

作者信息

Rengarajan Ronak, McCullough Peter A, Chowdhury Anima, Tecson Kristen M

机构信息

Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.

Baylor Heart and Vascular Institute, Dallas, Texas.

出版信息

Proc (Bayl Univ Med Cent). 2018 May 21;31(3):284-288. doi: 10.1080/08998280.2018.1463784. eCollection 2018 Jul.

Abstract

Familial chylomicronemia syndrome (FCS) is a rare lipid disorder posing significant clinical burdens on patients. Due to its rarity, variety of presentations, and lack of universal diagnostic criteria, patients see an average of five physicians before diagnosis. We screened adults for a triglyceride level ≥1000 mg/dL from September 2015 to September 2016 and a history of pancreatitis and performed a thorough chart review on those who met the criteria. An adjudication panel used a definition that also called for supportive information including history of hypertriglyceridemia or family history of pancreatitis/hypertriglyceridemia. Among 297,891 adults with laboratory values available, 334 (0.11%) had triglyceride levels ≥1000 mg/dL, and 30 (9%) of those had pancreatitis. Most of these 30 patients were male (73%), had diabetes (90%), were taking a fibrate (93%), and were taking a statin (80%). The average body mass index was 32.5 ± 4.5 kg/m. Six cases were ruled out, primarily due to substance abuse and/or isolated pancreatitis. Of the 24 suspected FCS cases, the average maximum triglyceride level was 3085 ± 1211 mg/dL. Electronic screening methods based solely on triglycerides ≥1000 mg/dL and pancreatitis eliminated 99.99% of the population, enabling the adjudication panel to focus on 30 cases. In 24 cases, FCS could not be ruled out; hence, the prevalence of FCS may be as high as 1 in 12,413.

摘要

家族性乳糜微粒血症综合征(FCS)是一种罕见的脂质紊乱疾病,给患者带来了沉重的临床负担。由于其罕见性、临床表现多样以及缺乏通用的诊断标准,患者在确诊前平均要看五位医生。我们在2015年9月至2016年9月期间对成年人进行了筛查,筛选标准为甘油三酯水平≥1000mg/dL以及有胰腺炎病史,并对符合标准的患者进行了全面的病历审查。一个判定小组采用了一种定义,该定义还要求提供支持性信息,包括高甘油三酯血症病史或胰腺炎/高甘油三酯血症家族史。在297,891名有实验室检查结果的成年人中,334人(0.11%)甘油三酯水平≥1000mg/dL,其中30人(9%)有胰腺炎。这30名患者中大多数为男性(73%),患有糖尿病(90%),正在服用贝特类药物(93%),正在服用他汀类药物(80%)。平均体重指数为32.5±4.5kg/m²。排除了6例,主要原因是药物滥用和/或孤立性胰腺炎。在24例疑似FCS病例中,平均最高甘油三酯水平为3085±1211mg/dL。仅基于甘油三酯≥1000mg/dL和胰腺炎的电子筛查方法排除了99.99%的人群,使判定小组能够专注于30例病例。在24例病例中,不能排除FCS;因此FCS的患病率可能高达1/12,413。

相似文献

1
Identifying suspected familial chylomicronemia syndrome.
Proc (Bayl Univ Med Cent). 2018 May 21;31(3):284-288. doi: 10.1080/08998280.2018.1463784. eCollection 2018 Jul.
2
Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
Lipids Health Dis. 2023 Mar 28;22(1):43. doi: 10.1186/s12944-022-01768-x.
3
Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Endocr Pract. 2018 Aug;24(8):756-763. doi: 10.4158/EP-2018-0157.
4
Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome.
J Clin Endocrinol Metab. 2025 Mar 17;110(4):1158-1165. doi: 10.1210/clinem/dgae613.
5
Chylomicronemia syndrome: Familial or not?
J Clin Lipidol. 2020 Mar-Apr;14(2):201-206. doi: 10.1016/j.jacl.2020.01.014. Epub 2020 Jan 31.
6
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
J Clin Lipidol. 2018 Sep-Oct;12(5):1234-1243.e5. doi: 10.1016/j.jacl.2018.05.013. Epub 2018 May 31.
7
The burden of familial chylomicronemia syndrome in Canadian patients.
Lipids Health Dis. 2020 Jun 2;19(1):120. doi: 10.1186/s12944-020-01302-x.
8
Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
J Intern Med. 2020 Apr;287(4):340-348. doi: 10.1111/joim.13016. Epub 2020 Jan 8.
9
The burden of familial chylomicronemia syndrome from the patients' perspective.
Expert Rev Cardiovasc Ther. 2017 Nov;15(11):879-887. doi: 10.1080/14779072.2017.1372193. Epub 2017 Sep 11.
10
Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3473-e3482. doi: 10.1210/clinem/dgab360.

引用本文的文献

3
Brazilian Position Statement for Familial Chylomicronemia Syndrome - 2023.
Arq Bras Cardiol. 2023 Mar;120(4):e20230203. doi: 10.36660/abc.20230203.
4
Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP).
BMC Endocr Disord. 2020 Feb 11;20(1):22. doi: 10.1186/s12902-020-0502-0.

本文引用的文献

1
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
J Clin Lipidol. 2018 Sep-Oct;12(5):1234-1243.e5. doi: 10.1016/j.jacl.2018.05.013. Epub 2018 May 31.
2
The burden of familial chylomicronemia syndrome from the patients' perspective.
Expert Rev Cardiovasc Ther. 2017 Nov;15(11):879-887. doi: 10.1080/14779072.2017.1372193. Epub 2017 Sep 11.
3
APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Curr Med Chem. 2018;25(13):1567-1576. doi: 10.2174/0929867324666170609081612.
5
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study.
Expert Rev Cardiovasc Ther. 2017 May;15(5):415-423. doi: 10.1080/14779072.2017.1311786. Epub 2017 Apr 4.
6
Diagnostic algorithm for familial chylomicronemia syndrome.
Atheroscler Suppl. 2017 Jan;23:1-7. doi: 10.1016/j.atherosclerosissup.2016.10.002. Epub 2016 Dec 18.
7
Clinical and genetic features of 3 patients with familial chylomicronemia due to mutations in GPIHBP1 gene.
J Clin Lipidol. 2016 Jul-Aug;10(4):915-921.e4. doi: 10.1016/j.jacl.2016.03.009. Epub 2016 Mar 23.
8
Long-Term Costs and Consequences of Patients with Familial Chylomicronemia Syndrome - A Simulation Model Approach.
Value Health. 2014 Nov;17(7):A400. doi: 10.1016/j.jval.2014.08.908. Epub 2014 Oct 26.
10
Chylomicronaemia--current diagnosis and future therapies.
Nat Rev Endocrinol. 2015 Jun;11(6):352-62. doi: 10.1038/nrendo.2015.26. Epub 2015 Mar 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验